Replimune Group, Inc. (NASDAQ:REPL) Receives $20.83 Consensus Price Target from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been assigned an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $20.83.

Several brokerages have issued reports on REPL. Cantor Fitzgerald began coverage on Replimune Group in a report on Friday, June 20th. They issued an “overweight” rating for the company. Piper Sandler increased their price target on Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, June 2nd.

Replimune Group Trading Down 1.4%

NASDAQ:REPL opened at $9.33 on Wednesday. Replimune Group has a 1-year low of $6.44 and a 1-year high of $17.00. The business’s 50-day moving average price is $9.00 and its two-hundred day moving average price is $10.67. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $719.25 million, a price-to-earnings ratio of -3.04 and a beta of 0.63.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.25) earnings per share. On average, equities analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,952 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now directly owns 146,933 shares in the company, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sushil Patel sold 25,105 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $202,346.30. Following the transaction, the chief executive officer now owns 343,576 shares of the company’s stock, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Redmile Group LLC grew its stake in Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock valued at $59,406,000 after purchasing an additional 124,344 shares in the last quarter. Vanguard Group Inc. grew its stake in Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock valued at $37,372,000 after purchasing an additional 237,185 shares in the last quarter. Tang Capital Management LLC grew its stake in Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after purchasing an additional 1,500,000 shares in the last quarter. Finally, RTW Investments LP grew its stake in Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after purchasing an additional 931,223 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.